Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Synvisc approved, launched in South Africa

April 13, 1999

Celebrex approved as arthritis treatment in Switzerland

April 13, 1999

Idec's humanized murine antibody enters phase II testing for SLE

April 12, 1999

Metabolically stable antiadhesion agents in development at Daikin

April 8, 1999

Phytopharm assumes increased responsibility for development of unique botanical product

April 7, 1999

Roche, deCode Genetics close in on osteoarthritis disease-causing gene

April 7, 1999

FDA approves ANDA for Oruvail

April 7, 1999

Prosorba Column now available in U.S. for treatment of rheumatoid arthritis

April 6, 1999

Bioniche enters supply agreement with Sanova for Suplasyn

April 6, 1999

Anika to initiate Orthovisc phase III clinical study in U.S. and Canada

April 5, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...